EGFR-Non-Small Cell Lung Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

EGFR-Non-Small Cell Lung Cancer Emerging Therapy and TPP Insights

Thelansis’s “EGFR-Non-Small Cell Lung Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

EGFR-Non-Small Cell Lung Cancer Overview

EGFR-mutated non-small cell lung cancer (NSCLC) is a molecular subtype in which activating changes in the EGFR gene drive tumor growth. Symptoms may include cough, breathlessness, chest pain, or problems caused by metastases; brain involvement is important. Diagnosis relies on molecular testing of tumor tissue and/or blood, noting that a negative plasma test may not exclude a mutation. For advanced disease with common exon 19 deletions or exon 21 L858R mutations, options include osimertinib alone, osimertinib with platinum-pemetrexed, or amivantamab plus lazertinib. Exon 20 insertions and less common variants require different treatment choices. Although targeted therapy can control disease, resistance may develop through additional EGFR changes, bypass signaling, or tumor transformation. Repeat molecular testing at progression can guide subsequent therapy. Research is evaluating bispecific antibodies, antibody-drug conjugates, and rational combinations to extend disease control.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)